FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/논문
연구 도서관으로 돌아가기
PubMedReview

Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.

Pobee Elizabeth, Daziani Gloria, Gameli Prince S, Basile Giuseppe, Carlier Jeremy, Tini Anastasio
Journal of analytical toxicology2025DOI: 10.1093/jat/bkaf038
AlexamorelinExamorelinHexarelin

품질 점수

6/10

참조 문헌

0

피험자

비인간

Peptide Contacts 분석

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of Alexamorelin, Examorelin, Hexarelin in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: A solid contribution to Alexamorelin, Examorelin, Hexarelin research. Worth reading alongside other studies on the same compounds for a balanced picture.

주요 발견

The study identified N-acetylation as the primary metabolic pathway for alexamorelin, with C-terminal cleavage leading to examorelin formation. However, examorelin is not specific to alexamorelin consumption.

제한 사항

The study did not use human subjects and relied on in silico predictions and hepatocyte incubations, limiting its applicability to real-world scenarios.

이 연구를 어떻게 해석해야 하는지

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts 분석

Exploring the Metabolic Pathways of Alexamorelin: Challenges in Detecting Its Use

AlexamorelinExamorelinHexarelin

Unraveling Alexamorelin's Metabolic Pathways: New Insights but Challenges Persist

Published: May 16, 2026 | Source: Journal of analytical toxicology (2025) | Category: Alexamorelin, Examorelin, Hexarelin

Overview

A recent study published in the Journal of Analytical Toxicology has shed light on the metabolic pathways of alexamorelin, a synthetic peptide with growth hormone secretagogue properties. The research highlights the complexity of detecting this substance's use due to its rapid metabolism and transformation into other peptides like examorelin (hexarelin), which complicates efforts in doping control.

Study Background

Alexamorelin is a performance-enhancing drug that mimics natural hormones to boost growth hormone levels, making it a target for anti-doping regulations. However, identifying biomarkers of its consumption has been challenging due to the rapid and extensive metabolism by the liver. This study aimed to predict and characterize these metabolic pathways using computational tools and in vitro human hepatocyte models.

What the Research Found

The research team used GLORYx software to predict 21 potential metabolites of alexamorelin, with N-acetylation at either the C-terminal alanine or N-terminal lysine being the most likely transformation. After incubating alexamorelin with pooled human hepatocytes for three hours, only one specific metabolite was detected: examorelin (hexarelin), which results from cleavage of the C-terminal alanine residue.

What This Means for Peptide Users

The findings suggest that detecting alexamorelin's use may be more challenging than previously thought due to its rapid transformation into other peptides. Examorelin, a known growth hormone secretagogue, is not specific to alexamorelin consumption, complicating efforts in identifying the exact substance used by athletes or patients.

Limitations and Caveats

The study’s reliance on computational predictions and in vitro hepatocyte models limits its applicability to real-world scenarios involving human subjects. Additionally, the detection of examorelin rather than unique metabolites specific to alexamorelin poses significant challenges for doping control measures.

How This Compares to Previous Research

Previous studies have focused on identifying biomarkers through urine or blood samples from athletes and patients, but this study’s approach provides a more detailed understanding of the metabolic pathways involved. However, it also highlights the need for further research using human subjects to validate these findings in practical settings.

Our Analysis

PeptideVault's analysis suggests that while this study advances our knowledge of alexamorelin metabolism, its limitations underscore the complexity of detecting such substances accurately. The identification of examorelin as a primary metabolite raises questions about the specificity and reliability of current detection methods for performance-enhancing peptides like alexamorelin.

Key Takeaways

  • Complex Metabolism: Alexamorelin undergoes rapid metabolism, primarily through N-acetylation.
  • Challenges in Detection: The transformation into examorelin complicates efforts to detect alexamorelin specifically.
  • Need for Further Research: Studies using human subjects are necessary to validate these findings and improve detection methods.

Original Source

Citation: Pobee Elizabeth, Daziani Gloria, Gameli Prince S et al. (2025). Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.. Journal of analytical toxicology. DOI: 10.1093/jat/bkaf038

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

Peptide Contacts 연구 팀은 복잡한 발견을 피테이드 커뮤니티에게 이해하기 쉬운 언어로 작성했습니다. 항상 원문의 전체 방법론과 데이터를 참조하십시오. Alexamorelin에 대해 더 알아보기 연구 가이드.

참조 문헌

Pobee Elizabeth, Daziani Gloria, Gameli Prince S et al.. (2025). Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.. Journal of analytical toxicology. https://doi.org/10.1093/jat/bkaf038

PubMed에서 전체 텍스트 확인하기

관련 논문

더 알아보기

이 내용은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.